<DOC>
	<DOCNO>NCT00534287</DOCNO>
	<brief_summary>Severe sepsis septic shock disease infectious origin high risk death . Antibiotic therapy mandatory unknown whether one antibiotic alone sufficient initial therapy . The purpose study compare therapy meropenem alone combination meropenem plus moxifloxacin treatment severe sepsis/ septic shock . Patients randomly receive one two treatment least 7 day longer 14 day .</brief_summary>
	<brief_title>Comparison Two Antibiotic Regimen ( Meropenem Versus Meropenem+Moxifloxacin ) Treatment Severe Sepsis Septic Shock</brief_title>
	<detailed_description>Early intravenous empiric broad-spectrum antimicrobial therapy essential part sepsis therapy . Inadequacy empirical antibiotic therapy associate increased mortality rate . Carbapenems design empirical antimicrobial monotherapy . Combination therapy suggest efficiency remain proven . In study , antimicrobial monotherapy meropenem compare combination therapy meropenem moxifloxacin . It hypothesize superior antibiotic therapy associate low overall organ dysfunction sepsis . Study therapy last least 7 day unless microbiological result suggest otherwise . Study therapy may extend 14 day . Follow examination occur 28 90 day . This investigator initiate study supported German government ( bmbf ) unrestricted industrial grant .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Severe sepsis septic shock accord ACCP/SCCM criterion Onset severe sepsis septic shock &lt; 24 h Informed consent Effective contraception fertile woman Age &lt; 18 year Pregnancy Breastfeeding woman Pretreatment meropenem , imipenem , ertapenem within last 4 week ( &gt; 1 daily dosage ) Pretreatment moxifloxacin , ciprofloxacin , levofloxacin within last 4 week ( &gt; 1 daily dosage ) Pretreatment pseudomonas effective cephalosporin ( cefepime , ceftazidim , cefpirom ) piperacillin within last 48 hour ( &gt; 1 daily dosage ) . Pretreatment chinolones within last 4 week ( &gt; 1 daily dosage ) Presence infection guideline recommend another antimicrobial therapy study medication ( i.e . endocarditis ) Evidence strong clinical suspicion microorganism study medication know ineffective ( i.e . tuberculosis , MRSA VREinfection ) Known allergy meropenem moxifloxacin Tendon disease injury due past quinolone therapy Congenital acquire prolongation QTinterval Concomitant medication prolongs QTinterval Electrolyte imbalance , especially uncorrected hypokalemia Clinically relevant bradycardia Clinically relevant cardiac dysfunction reduce leftventricular ejection fraction Symptomatic arrhythmias medical history Significant hepatic impairment ( ChildPugh C ) elevation liver enzymes &gt; 5x upper normal range No commitment full patient support ( i.e . DNR order ) Patient 's death consider imminent due coexist disease Concomitant participation another study study participation last 30 day . Relationship patient study team member ( i.e . colleague , relative )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>sepsis</keyword>
	<keyword>antibiotic</keyword>
	<keyword>carbapenems</keyword>
	<keyword>fluoroquinolones</keyword>
	<keyword>Severe sepsis septic shock</keyword>
</DOC>